CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Summary and Questions for the Committee Blood Products Advisory.

Slides:



Advertisements
Similar presentations
Maintaining a Safe and Adequate Supply of Donated Blood During a Severe Emergency Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs, OBRR,
Advertisements

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.
Blood Donor Written Statement of Understanding
It’s All Good We All Have a Purpose Raise the Roof How Low Can You Go?
Epoetin Alfa & Increased Mortality Maria Shin, Pharm.D. Pharmacy Resident (PGY-1) Kingsbrook Jewish Medical Center Clinical Instructor of Pharmacy Practice.
Hemoglobin Determination. Hemoglobin — Found in the RBC. — Responsible for carrying oxygen to all cells in the body. — Also binds to carbon dioxide and.
Adapting AABB Donor Regulation at KCBB. Why? Blood safety starts by bleeding safe Blood donors “Safe Blood starts with me” BTS need to Implement adequate.
Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.
Mitochondrial Manipulation Technologies: Preclinical Considerations
Iron Status in Blood Donors Barbara J. Bryant, MD University of Texas Medical Branch Galveston, Texas and Department of Transfusion Medicine National Institutes.
Microhematocrit.
Current standards, donor safety, and blood supply
Dengue Virus and Its Risk to the U.S. Blood Supply
1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,
CBER 1 Current standards, donor safety and blood supply Orieji Illoh, MD Office of Blood Research and Review Center for Biologics Evaluation and Research.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.
Draft Guidance: Collection of Platelets by Automated Methods Comments to the Docket and Questions for the Committee Alan E. Williams, Ph.D. Director,
Background Donor Suitability Consultation was held in Atlanta June 26-27, 2001 To review and consult on the 1994 CDC Guidelines for Preventing Transmission.
Donor Selection Criteria Dr. Mindy Goldman Transfusion Medicine Residents May 24, 2011.
CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Introduction Blood Products Advisory Committee July 27, 2010.
Risks and Indications for RBCs Transfusions David Stroncek, MD Chief, Laboratory Services Section Department of Transfusion Medicine, Clinical Center,
Proposed changes to hemoglobin and donation interval criteria for whole blood donors: Projected impact on current donor base Anne Eder, MD PhD Executive.
Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. The HIV epidemic in the U.S.A. is generally recognized to have started just after Currently MSM.
Update: Lowering Measles Antibody Lot Release Specification in IGIV/IGSC Blood Products Advisory Committee May 1, 2008 Dorothy Scott, M.D. Division of.
Iron Deficiency Anemia
Interagency Taskforce to Prevent Childhood Lead Poisoning from Non-paint Related Sources Mary Jean Brown, ScD, RN Chief, Childhood Lead Poisoning Prevention.
Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.
Rational Hematological Monitoring for Clozapine-Treated Patients.
Current Considerations on Plasma for Further Manufacturing Obtained from Whole Blood Donors Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs,
Hydration Best Practice Making a difference. Water is important Water is essential to health, and is one of six basic nutrients for life, but is often.
Apheresis Blood Components
Monthly Journal article review: Vimmi Kang PGY 2
Review of literature and report of experience with erythropoietin in ESRD populations Summary to FDA Cardio Renal Committee J. Michael Lazarus, M.D. CMO.
CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.
Equilibrium Concept Review
Question 1 (Hgb Target, Hemodialysis) Vote: yes/no. Based on the available data, primarily derived from the Normal Hematocrit study, should the ESA product.
Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.
Jacques Vanier ICAO EUR/NAT Regional Officer Almaty, 5 to 9 September 2005 SAFETY MANAGEMENT SYSTEMS RISK VERSUS SAFETY.
Blood Center Experience with Double Red Cell Collections by Apheresis: Adverse Events and Impact on Capacity Brian Custer, Hany Kamel, Marj Bravo Peter.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Mid – Late 1970’s Emergence of recombinant DNA technology Concerns among both scientific community and general public:  Public health and safety  Environmental.
A & P Lab 2 Indian River State College. Polycythemia Anemia.
Modeling Risk of vCJD in US Donors – Residual Risk and Efficiency of Donor Deferral Alan E. Williams, Ph.D. Director, Division of Blood Applications Office.
Hong Yang, Ph.D. Office of Biostatistics and Epidemiology FDA-Center for Biologics Evaluation & Research Transmissible Spongiform Encephalopathies Advisory.
Hemoglobin Device Regulation Josephine Bautista, M.S., MT (ASCP) Senior Advisor for IVD Regulation DRB/DBA/OBRR/CBER Workshop: Hemoglobin standards and.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
27 June 2000Victor F. C. Raczkowski, M.D.1 Benefit-Risk Reevaluation of Marketed Drugs Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.
Priority Research Direction (use one slide for each) Key challenges What will you do to address the challenges?Brief overview of the barriers and gaps.
Proposed Workshop: Hemoglobin Standards and Maintenance of Iron Stores in Blood Donors Blood Product Advisory Committee April 29, 2011.
Transfusion Related Acute Lung Injury (TRALI)
Confidential Unit Exclusion Donors may be given the opportunity to indicate confidentially whether their blood is or is not suitable for transfusion to.
FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.
Buy dry fruits online India Buy dry fruit online India from the excellent online store of dry fruit & also buy spices online India, this store provides.
Anemia of Prematurity.
Objective: To assess the prevalence of anemia in a sample of Jordanian pregnant women and to find out whether packed cell volume (PCV) affected by the.
Introduction To Medical Technology
Microhematocrit.
Patient A.
Lead Exposure & Breastfeeding
Monthly Journal article review: Vimmi Kang PGY 2
Anemia is a condition where the blood lacks adequate healthy red blood cells that carry oxygen to the tissues of the body. Iron-deficiency anemia is due.
Anemia Interventions in Low Iron Deficiency Settings - Low-dose Pre-natal Iron Supplementation and MNPs Technical Briefs prepared for Sierra Leone Ministry.
Retrospective analysis of capillary hemoglobin recovery in nearly 1 200 000 blood donor returns by Pia Niittymäki, Mikko Arvas, Antti Larjo, Pirkko Mattila,
Challenges and Emerging Solutions in Anemia Management Explored
Northern Cancer Alliance Colorectal Symptoms Assessment Pathway
Presentation transcript:

CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Summary and Questions for the Committee Blood Products Advisory Committee July 27, 2010

CBER 12 Key issues Consideration of the balance between donor safety and blood supply Donor safety issues Hemoglobin standards Interdonation interval Blood supply issues Impact of any changes in hemoglobin standards or interdonation interval on blood supply

CBER 23 Current FDA regulatory requirements 21CFR 640.3(b)(3) – Blood hemoglobin level no less than 12.5g/dL or hematocrit no less than 38% 21CFR 640.3(b) – Interdonation interval: Not more than once every 8 weeks ~ 6 donations/year

CBER 34 International Standards CountryMinimum hemoglobin Interdonation interval or frequency per year United States days Canada days United Kingdom12.5 for women 13.5 for men 112 days Australia12.0 for women 13.0 for men 84 days Netherlands12.5 for women 13.5 for men Women: 18 weeks, 3x/year Men:10 – 11 weeks, 5x/year Hong Kong11.5 for women 13.0 for men Women: 3x/year Men: 4x/year

CBER 5 Hemoglobin / Hematocrit Standards in Male Donors Possible options – 12.5g/dL – 13.0g/dL – 13.5g/dL

CBER 56 Hemoglobin / Hematocrit Standards in Female Donors – 12.5g/dL – 12.0g/dL Possible Options

CBER 7 Hemoglobin / Hematocrit Standards in Female Donors Possible Options – 12.5g/dL – 12.0g/dL

CBER 68 Effect of frequent donations Studies show that iron deficiency occurs more often among frequent blood donors. Iron deficiency may exist despite hemoglobin levels within the acceptable range Anemia related to iron deficiency anemia may lead to donor deferral and loss

CBER 79 Increasing the interdonation interval May allow more time for iron recovery May decrease the risk of iron deficiency May decrease future donor deferral for low hemoglobin

CBER 810 Summary: Donor safety issues Raising Hb standard for men – May prevent donations from “anemic” men Lowering Hb standard for women – May result in a modest increase in iron deficiency Increasing interdonation interval – May prevent iron deficiency in frequent blood donors

CBER 911 Summary- Blood supply issues Potential gain of female blood donors – If hemoglobin standard is dropped Potential loss of male blood donors – If hemoglobin standard is raised Potential loss of male and female donors – If the interdonation interval is increased

CBER 1012 Questions for the Committee 1.Does available scientific evidence support changing the donor hemoglobin acceptance standard for males? a) If yes, what hemoglobin acceptance standards does the committee recommend?

CBER 1113 Questions for the Committee 2.Does available scientific evidence support changing the donor hemoglobin acceptance standard for females? a) If yes, what hemoglobin acceptance standards does the committee recommend?

CBER 1214 Questions for the Committee 3.Please comment on the risks and benefits of extending interdonation intervals as a strategy to prevent iron deficiency in male donors.

CBER 1315 Questions for the Committee 4.Please comment on the risks and benefits of extending interdonation intervals as a strategy to prevent iron deficiency in female donors.

CBER 1416 Questions for the Committee 5.If any changes to the hemoglobin standard or interdonation interval were to be made, what mitigations can be considered to lessen possible adverse effects on the blood supply?